Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

Mild traumatic brain injury (mTBI), a significant public health concern, is diagnosed by clinical assessment and computed tomography (CT) scans, while glial fibrillary acidic protein (GFAP) and ...

The T-cell malignancies market is driven by the rising incidence of these cancers, advancements in treatment options, and ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 ...

Researchers from the Universitat Jaume I of Castelló (Spain) and the Max Planck Institute (Germany) have developed new ...

Plasma biomarkers differ in adolescents with sport-related concussions and uninjured samples, justifying their use to understand concussion neuropathology.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) found its stock slumping Monday. The AI-driven biotherapeutic research and technology company announces its significant contribution to a groundbreaking ...

ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology ...

Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the ...